News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis’ Capital Markets Day on October 13: Agenda and Registration Details

October 6, 2022

Stockholm, Sweden, October 6, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the Agenda and Registration Details for the Company’s Capital Markets Day on Thursday October 13, 2022, in Stockholm, Sweden, for investors, analysts and media.
Time: Thursday, October 13, 2022, at 1:00 pm – 4:00 pm CEST
Venue: Erik Penser Bank, Apelbergsgatan 27, Stockholm, Sweden
Registration (to attend in person): Please register here
Webcast (no preregistration required): Please follow this link
During the event, the Company will provide an update and review of its strategy and pipeline. The presentations will focus on the Company’s drug candidates and the related unmet medical need they will address, development plans, commercial opportunities, and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team and Board, as well as invited key opinion leaders. Presentations will be held in English. The webcast will also be available on Egetis webpage after the event.


Time Subject Presenter(s)
13:00 Welcome, Corporate strategy and overview Nicklas Westerholm, CEO
13:15 MCT8 deficiency & clinical experience with Emcitate Dr Edward Visser, Erasmus Medical Center
13:40 Development paths for Emcitate in Europe and the US Dr Peder Walberg, Operative Director of the Board
13:55 Q&A: MCT8 deficiency & Emcitate development Visser, Walberg, Sjöblom, Westerholm
14:10 Global plans for commercializing Emcitate Dr Henrik Krook, VP Commercial
14:20 Market access & commercialization in the US Sara Melton, President Egetis North America
14:30 Q&A: Emcitate commercialization Walberg, Krook, Melton, Westerholm
14:45 Break
15:00 Paracetamol overdose & clinical experience with Aladote Prof. James Dear, Edinburgh University
15:20 Development paths for Aladote in Europe and the US Dr Kristina Sjöblom, CMO
15:30 Commercial opportunity for Aladote Dr Henrik Krook, VP Commercial
15:35 Aladote Q&A Dear, Sjöblom, Krook, Westerholm
15:45 Summary of the day Nicklas Westerholm, CEO
15:55 Concluding remarks Thomas Lönngren, Chair of the Board
16:00 End



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10